PGEN Share Price Performance
US$7.23
5.49 (315.52%)
50.1% undervalued intrinsic discount
US$14.50
Fair Value
Price US$7.23
AnalystConsensusTarget US$14.50
AnalystHighTarget US$18.00
Fair ValueUS$14.50
Share Pricen/a
New Narrative • Aug 06
Precigen, Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 47 Fair Values set on narratives written by author
PGEN Community Narratives
AN
Fair Value
·Fair Value US$14.5 50.1% undervalued intrinsic discount
Gene And Immunotherapy Expansion Will Drive Durable Long Term Opportunity
0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
Fair Value
·Fair Value US$18 59.8% undervalued intrinsic discount
AdenoVerse Platform And First-Line RRP Therapy Will Shape Powerful Long-Term Earnings Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Gene And Immunotherapy Expansion Will Drive Durable Long Term Opportunity
Precigen’s story hinges on whether its new gene-based treatment can quickly replace repeat surgeries for a stubborn throat disease and become a long-lasting option doctors and insurers embrace. The upside grows if it expands to children and new regions, but a slower rollout, pricing pushback, or later safety concerns could change the outlook.Read more
AN
US$14.5
50.1% undervalued intrinsic discount
Fair Value
Profit Margin
60.51%
Future PE
21.57x
Price in 2029
US$17.89
AdenoVerse Platform And First-Line RRP Therapy Will Shape Powerful Long-Term Earnings Potential
Precigen is turning a newly approved treatment for a rare throat condition into a real commercial launch, with broad insurance coverage and early signs it could become the go-to option for many patients. The bigger question is whether this early demand lasts—and whether its broader cancer programs can deliver enough to reduce reliance on a single product.Read more
AN
US$18
59.8% undervalued intrinsic discount
Fair Value
Profit Margin
60.18%
Future PE
26.08x
Price in 2029
US$22.24
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
AdenoVerse Platform And First-Line RRP Therapy Will Shape Powerful Long-Term Earnings Potential
Fair Value: US$18 59.8% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
PGEN: Orphan Exclusivity And Early RRP Uptake Will Drive Future Upside
Fair Value: US$14.5 50.1% undervalued intrinsic discount
9 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Precigen, Inc. Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -0.94
- 53.01%
- -392.81%
- 215.4%
About PGEN
- Founded
- 1998
- Employees
- 160
- CEO
- WebsiteView website
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
